Haleon (LON:HLN) Board of Directors Authorizes Stock Repurchase Program

Key Points

• Haleon approved a £500 million share repurchase program, allowing it to buy back up to 1.8% of its outstanding shares through open-market purchases.
• Shares fell to GBX 316.60 during trading, near their 12-month low, while analysts’ average rating remained “Hold” with an average price target of GBX 387.80.
• Although Haleon maintained its profit guidance, weaker-than-expected sales momentum and disruptions in North America, China and Brazil prompted the company to reduce its 2026 organic revenue-growth forecast to approximately 2.5%.

Haleon (LON:HLN - Get Free Report) declared that its board has approved a share repurchase program on Thursday, October 29th, RTT News reports. The company plans to buy back £500 million in shares. This repurchase authorization allows the company to purchase up to 1.8% of its shares through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Haleon Stock Performance

Shares of LON HLN traded down GBX 57.40 during mid-day trading on Thursday, hitting GBX 316.60. The company had a trading volume of 1,048,323,188 shares, compared to its average volume of 32,679,883. Haleon has a 12 month low of GBX 310.50 and a 12 month high of GBX 433.60. The firm has a market cap of £27.85 billion, a P/E ratio of 17.49, a PEG ratio of 1.49 and a beta of 0.24. The business's 50-day simple moving average is GBX 353.77 and its 200-day simple moving average is GBX 360.62. The company has a debt-to-equity ratio of 50.38, a current ratio of 0.69 and a quick ratio of 0.93.

Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. As a group, analysts predict that Haleon will post 19.50 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HLN shares. Deutsche Bank Aktiengesellschaft dropped their price target on Haleon from GBX 335 to GBX 320 and set a "sell" rating on the stock in a research report on Wednesday, September 9th. Royal Bank Of Canada increased their price objective on Haleon from GBX 370 to GBX 390 and gave the company a "sector perform" rating in a research report on Tuesday, August 11th. Berenberg Bank raised their price objective on shares of Haleon from GBX 512 to GBX 514 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a GBX 400 target price on shares of Haleon in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of GBX 387.80.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon launched a £500 million share buyback, which should support earnings per share, return capital to investors and help fund employee share plans. Management also maintained its profit guidance. Haleon launches £500 million share buyback programme
• Neutral Sentiment: Third-quarter organic revenue increased 2.6%, while Haleon’s consumer-health portfolio continued to grow overall. However, the result was below management’s expectations, making the buyback appear more defensive than growth-driven. Haleon Q3 2026 trading update
• Negative Sentiment: Haleon reduced its fiscal 2026 organic revenue-growth forecast to approximately 2.5%, from a previous range of 3% to 5%. The downgrade reinforces investor concerns that sales momentum is slowing. Haleon trims 2026 growth outlook
• Negative Sentiment: Weaker-than-expected cough, cold and flu consumption reduced North American orders, while a raw-material classification change disrupted OTC-registered Centrum products in China. Haleon also expects a fourth-quarter revenue impact from accelerating a go-to-market change in Brazil. Haleon cuts revenue growth forecast

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.